| A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world Sett | — | rekrutiert |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment | Phase III | rekrutiert |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradi | Phase III | rekrutiert |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Co | Phase II / Phase III | rekrutiert |
| A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Scle | — | rekrutiert |
| A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor f | — | rekrutiert |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan | Phase III | rekrutiert |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men | Phase III | rekrutiert |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cance | Phase III | rekrutiert |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants Wi | Phase III | rekrutiert |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previous | Phase III | rekrutiert |
| A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomi | Phase III | rekrutiert |
| A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseas | Phase III | rekrutiert |
| Abbott Structural Heart Device Registry | — | rekrutiert |
| Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochem | Phase III | rekrutiert |
| An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psor | — | rekrutiert |
| Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer | ohne Phasenangabe | rekrutiert |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase III | rekrutiert |
| Clinical Performance of the New Plasma Filter PX2 in TPE Treatments | ohne Phasenangabe | rekrutiert |
| Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Loca | Phase IV | rekrutiert |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagl | Phase III | rekrutiert |
| Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock | ohne Phasenangabe | rekrutiert |
| Endometrial Cancer Lymphadenectomy Trial | ohne Phasenangabe | rekrutiert |
| European Disease Registry on Retinopathy of Prematurity (ROP) | — | rekrutiert |
| Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With | Phase II | rekrutiert |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab i | Phase II / Phase III | rekrutiert |
| Fosfomycin I.v. for Treatment of Severely Infected Patients | — | rekrutiert |
| GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, T | — | rekrutiert |
| Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multi | Phase III | rekrutiert |
| International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lym | Phase III | rekrutiert |
| International HIT-MED Registry (I-HIT-MED) | — | rekrutiert |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH | Phase III | rekrutiert |
| LANDMARK Trial: a Randomised Controlled Trial of Myval THV | ohne Phasenangabe | rekrutiert |
| NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometr | — | rekrutiert |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HE | Phase II | rekrutiert |
| PROCARE - PROstate Cancer Real World Evidence Registry | — | rekrutiert |
| PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and | — | rekrutiert |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial | Phase II / Phase III | rekrutiert |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in | Phase III | rekrutiert |
| Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With New | Phase III | rekrutiert |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blin | Phase II | rekrutiert |
| Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years Wi | — | rekrutiert |
| Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Pro | — | rekrutiert |
| Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy | Phase II | rekrutiert |
| Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Ac | — | rekrutiert |
| Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearran | Phase III | rekrutiert |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, | Phase II | rekrutiert |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in | Phase III | rekrutiert |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM AL | Phase III | rekrutiert |